Dr. Tripathy Discusses Breast Cancer Gene Profiling

Debu Tripathy, MD
Published: Friday, Aug 12, 2011

Debu Tripathy, MD, professor of medicine and co-leader of the Women’s Cancer Program at the University of Southern California Norris Comprehensive Cancer Center, discusses the primary ways that multigene profiling is used in early stage breast cancer.

Multigene gene profiling, such as the Oncotype DX score, help determine treatment in patients that are estrogen receptor (ER) positive or progesterone receptor (PR) positive and HER2 neu negative with early stage cancers. The recurrence score is used most in node negative breast cancer because the patients with an intermediate to high recurrence score are a subset of early breast cancer patients that derive the most benefit from chemotherapy.
Debu Tripathy, MD, professor of medicine and co-leader of the Women’s Cancer Program at the University of Southern California Norris Comprehensive Cancer Center, discusses the primary ways that multigene profiling is used in early stage breast cancer.

Multigene gene profiling, such as the Oncotype DX score, help determine treatment in patients that are estrogen receptor (ER) positive or progesterone receptor (PR) positive and HER2 neu negative with early stage cancers. The recurrence score is used most in node negative breast cancer because the patients with an intermediate to high recurrence score are a subset of early breast cancer patients that derive the most benefit from chemotherapy.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x